Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.
Nishihori T et al. Curr Hematol Malig Rep. 2016 Feb 22. [Epub ahead of print].
Fully automated classification of bone marrow infiltration in low-dose CT of patients with multiple myelomabased on probabilistic density model and supervised learning.
Martínez-Martínez F et al. Comput Biol Med. 2016 Feb 8;71:57-66. doi: 10.1016/j.compbiomed.2016.02.001. [Epub ahead of print].
99mTc-MIBI scintigraphy in the diagnosis of multiple myeloma.
Chrabański O et al. Pol Arch Med Wewn. 2016 Feb 12. doi: 10.20452/pamw.3290. [Epub ahead of print].
High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.
Wang H et al. Br J Cancer. 2016 Feb 16;114(4):463-8. doi: 10.1038/bjc.2016.11. Epub 2016 Feb 4.
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR).
Willenbacher W et al. Leuk Lymphoma. 2016 Feb 16:1-12. [Epub ahead of print].
Stereotactic biopsy approach to the upper clivus through the middle fossa floor that avoids pneumatised cavities and the intradural compartment.
Magrassi L et al. Acta Neurochir (Wien). 2016 Feb 6. [Epub ahead of print].
Monitoring free light chains in serum using mass spectrometry.
Barnidge DR et al. Clin Chem Lab Med. 2016 Feb 4. pii: /j/cclm.ahead-of-print/cclm-2015-0917/cclm-2015-0917.xml. doi: 10.1515/cclm-2015-0917. [Epub ahead of print].
Inter-station intensity standardization for whole-body MR data.
Dzyubachyk O et al. Magn Reson Med. 2016 Feb 1. doi: 10.1002/mrm.26098. [Epub ahead of print].